Virus Dataset Sample Info

> Dataset: 23236287 Search Result

Summary

Item	Summary
Project	23236287
Virus Name	HBV
Sample Number	24
Disease	Hepatocellular carcinoma (HCC)
Country	China

Sample

ID	Sample ID	Age	Gender	Origin	Detail
1	C7	45	M	China	View
2	C9	53	M	China	View
3	C12	51	M	China	View
4	C13	60	M	China	View
5	C16	49	M	China	View
6	C17	63	M	China	View
7	C18	69	M	China	View
8	C19	36	M	China	View
9	C21	70	F	China	View
10	C22	67	M	China	View
11	C23	63	M	China	View
12	C24	59	F	China	View
13	C25	51	M	China	View
14	C28	64	M	China	View
15	C100	53	F	China	View
16	C101	39	M	China	View
17	C102	46	M	China	View
18	C103	48	M	China	View
19	C104	34	M	China	View
20	C105	46	F	China	View
21	C106	24	F	China	View
22	C107	46	M	China	View
23	C108	53	M	China	View
24	C109	75	M	China	View
25	N7	45	M	China	View
26	N9	53	M	China	View
27	N12	51	M	China	View
28	N13	60	M	China	View
29	N16	49	M	China	View
30	N17	63	M	China	View
31	N18	69	M	China	View
32	N19	36	M	China	View
33	N21	70	F	China	View
34	N22	67	M	China	View
35	N23	63	M	China	View
36	N24	59	F	China	View
37	N25	51	M	China	View
38	N28	64	M	China	View
39	N100	53	F	China	View
40	N101	39	M	China	View
41	N102	46	M	China	View
42	N103	48	M	China	View
43	N104	34	M	China	View
44	N105	46	F	China	View
45	N106	24	F	China	View
46	N107	46	M	China	View
47	N108	53	M	China	View
48	N109	75	M	China	View

Literature

Item	Summary
PMID	23236287
Title	Recurrent Targeted Genes of Hepatitis B Virus in the Liver Cancer Genomes Identified by a Next-Generation Sequencing-Based Approach
Abstract	Integration of the viral DNA into host chromosomes was found in most of the hepatitis B virus (HBV)-related hepatocellular carcinomas (HCCs). Here we devised a massive anchored parallel sequencing (MAPS) method using next-generation sequencing to isolate and sequence HBV integrants. Applying MAPS to 40 pairs of HBV-related HCC tissues (cancer and adjacent tissues), we identified 296 HBV integration events corresponding to 286 unique integration sites (UISs) with precise HBV-Human DNA junctions. HBV integration favored chromosome 17 and preferentially integrated into human transcript units. HBV targeted genes were enriched in GO terms: cAMP metabolic processes, T cell differentiation and activation, TGF beta receptor pathway, ncRNA catabolic process, and dsRNA fragmentation and cellular response to dsRNA. The HBV targeted genes include 7 genes (PTPRJ, CNTN6, IL12B, MYOM1, FNDC3B, LRFN2, FN1) containing IPR003961 (Fibronectin, type III domain), 7 genes (NRG3, MASP2, NELL1, LRP1B, ADAM21, NRXN1, FN1) containing IPR013032 (EGF-like region, conserved site), and three genes (PDE7A, PDE4B, PDE11A) containing IPR002073 (3', 5'-cyclic-nucleotide phosphodiesterase). Enriched pathways include hsa04512 (ECM-receptor interaction), hsa04510 (Focal adhesion), and hsa04012 (ErbB signaling pathway). Fewer integration events were found in cancers compared to cancer-adjacent tissues, suggesting a clonal expansion model in HCC development. Finally, we identified 8 genes that were recurrent target genes by HBV integration including fibronectin 1 (FN1) and telomerase reverse transcriptase (TERT1), two known recurrent target genes, and additional novel target genes such as SMAD family member 5 (SMAD5), phosphatase and actin regulator 4 (PHACTR4), and RNA binding protein fox-1 homolog (C. elegans) 1 (RBFOX1). Integrating analysis with recently published whole-genome sequencing analysis, we identified 14 additional recurrent HBV target genes, greatly expanding the HBV recurrent target list. This global survey of HBV integration events, together with recently published whole-genome sequencing analyses, furthered our understanding of the HBV-related HCC.